ChemoRad nanoparticles: A novel multifunctional nanoparticle platform for targeted delivery of concurrent chemoradiation

Nanomedicine

Volumn 5, Issue 3, 2010, Pages 361-368

  Wang, Andrew Z ^a,b   Yuet, Kai ^c   Zhang, Liangfang ^d   Gu, Frank X ^e   Huynh Le, Minh ^c   Radovic Moreno, Aleksandar F ^c   Kantoff, Philip W ^b   Bander, Neil H ^f   Langer, Robert ^c   Farokhzad, Omid C ^a,c  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e UNIVERSITY OF WATERLOO   (Canada)

^f WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

Biologically targeted nanoparticle; ChemoRad NP; Chemoradiation; Chemoradiation nanoparticle; Nanomedicine; Nanotechnology; Prostate cancer

Indexed keywords

1,2 DITETRADECANOYL SN GLYCERO 3 PHOSPHOETHANOLAMINE; DISTEAROYLPHOSPHATIDYLETHANOLAMINE; DOCETAXEL; GLYCEROPHOSPHOETHANOLAMINE; INDIUM 111; NANOPARTICLE; PENTETIC ACID; PHOSPHATIDYLETHANOLAMINE; POLYGLACTIN; UNCLASSIFIED DRUG; YTTRIUM 90;

ARTICLE; BIOCOMPATIBILITY; BIODEGRADABILITY; CELL STRAIN LNCAP; CHELATION; CHEMORADIOTHERAPY; CONTROLLED STUDY; DRUG EFFICACY; DRUG RELEASE; MOLECULARLY TARGETED THERAPY; NANOENCAPSULATION; PARTICLE SIZE; PRIORITY JOURNAL; PROSTATE CANCER; SURFACE CHARGE;

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL SURVIVAL; COMBINED MODALITY THERAPY; HUMANS; INDIUM RADIOISOTOPES; MALE; NANOPARTICLES; PROSTATIC NEOPLASMS; TAXOIDS; YTTRIUM RADIOISOTOPES;

EID: 77951223396     PISSN: 17435889     EISSN: None     Source Type: Journal    
DOI: 10.2217/nnm.10.6     Document Type: Article

References (25)

1. Seiwert TY, Salama JK, Vokes EE: The concurrent chemoradiation paradigm - general principles. Nat. Clin. Pract. 4(2), 86-100 (2007).
2. Maeda H, Wu J, Sawa T, Matsumura Y, Hori K: Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J. Control. Release 65(1-2), 271-284 (2000). (Pubitemid 30122932)
3. Sells RA, Owen RR, New RR, Gilmore IT: Reduction in toxicity of doxorubicin by liposomal entrapment. Lancet 2(8559), 624-625 (1987). (Pubitemid 17131367)
4. Kim SH, Jeong JH, Chun KW, Park TG: Target-specific cellular uptake of PLGA nanoparticles coated with poly(l-lysine)-poly(ethylene glycol)-folate conjugate. Langmuir 21(19), 8852-8857 (2005).
5. Oyewumi MO, Yokel RA, Jay M, Coakley T, Mumper RJ: Comparison of cell uptake, biodistribution and tumor retention of folate-coated and PEG-coated Gadolinium nanoparticles in tumor-bearing mice. J. Control. Release 95(3), 613-626 (2004). (Pubitemid 38340510)
6. Bagalkot V, Farokhzad OC, Langer R, Jon S: An aptamer-doxorubicin physical conjugate as a novel targeted drug-delivery platform. Angew. Chem. Int. Ed. Engl. 45(48), 8149-8152 (2006). (Pubitemid 44974149)
7. Bagalkot V, Zhang L, Levy-Nissenbaum E et al.: Quantum dot-aptamer conjugates for synchronous cancer imaging, therapy, and sensing of drug delivery based on bi-fluorescence resonance energy transfer. Nano Lett. 7(10), 3065-3070 (2007). (Pubitemid 350132931)
8. Farokhzad OC, Cheng J, Teply BA et al.: Targeted nanoparticle-aptamer bioconjugates for cancer chemotherapy in vivo. Proc. Natl Acad. Nat. Sci. USA 103(16), 6315-6320 (2006).
9. Farokhzad OC, Jon S, Khademhosseini A, Tran TN, Lavan DA, Langer R: Nanoparticle-aptamer bioconjugates: a new approach for targeting prostate cancer cells. Cancer Res. 64(21), 7668-7672 (2004). (Pubitemid 39446893)
10. Wang AZ, Bagalkot V, Vasilliou CC et al.: Superparamagnetic iron oxide nanoparticle- aptamer bioconjugates for combined prostate cancer imaging and therapy. ChemMedChem 3(9), 1311-1315 (2008).
11. Zhang L, Radovic-Moreno AF, Alexis F et al.: Co-delivery of hydrophobic and hydrophilic drugs from nanoparticle-aptamer bioconjugates. ChemMedChem 2(9), 1268-1271 (2007).
12. Kirpotin DB, Drummond DC, Shao Y et al.: Antibody targeting of long-circulating lipidic nanoparticles does not increase tumor localization but does increase internalization in animal models. Cancer Res. 66(13), 6732-6740 (2006). (Pubitemid 44085631)
13. Shenoy D, Little S, Langer R, Amiji M: Poly(ethylene oxide)-modified poly(b-amino ester) nanoparticles as a pH-sensitive system for tumor-targeted delivery of hydrophobic drugs: part 2. In vivo distribution and tumor localization studies. Pharm. Res. 22(12), 2107-2114 (2005). (Pubitemid 41821590)
14. Gabizon A, Chisin R, Amselem S et al.: Pharmacokinetic and imaging studies in patients receiving a formulation of liposome-associated adriamycin. Br. J. Cancer 64(6), 1125-1132 (1991).
15. Perrault SD, Walkey C, Jennings T, Fischer HC, Chan WC: Mediating tumor targeting efficiency of nanoparticles through design. Nano Lett. 9(5), 1909-1915 (2009).
16. Zhang L, Chan JM, Gu FX et al.: Self-assembled lipid-polymer hybrid nanoparticles: a robust drug delivery platform. ACS Nano 2(8), 1696-1702 (2008).
17. Lupold SE, Hicke BJ, Lin Y, Coffey DS: Identification and characterization of nuclease-stabilized RNA molecules that bind human prostate cancer cells via the prostate-specific membrane antigen. Cancer Res. 62(14), 4029-4033 (2002). (Pubitemid 34791070)
18. Cooper MS, Sabbah E, Mather SJ: Conjugation of chelating agents to proteins and radiolabeling with trivalent metallic isotopes. Nat. Protoc. 1(1), 314-317 (2006).
19. Ljungberg M, Frey E, Sjogreen K, Liu X, Dewaraja Y, Strand SE: 3D absorbed dose calculations based on spect: evaluation for 111-In/90-Y therapy using Monte Carlo simulations. Cancer Biother. Radiopharm. 18(1), 99-107 (2003). (Pubitemid 36307471)
20. Bhargava KK, Acharya SA: Labeling of monoclonal antibodies with radionuclides. Semin. Nucl. Med. 19(3), 187-201 (1989).
21. Zhang L, Chan JM, Gu FX et al.: Self-assembled lipid - polymer hybrid nanoparticles: a robust drug delivery platform. ACS Nano 2(8), 1696-1702 (2008).
22. Ryan SM, Mantovani G, Wang X, Haddleton DM, Brayden DJ: Advances in pegylation of important biotech molecules: delivery aspects. Expert Opin. Drug Deliv. 5(4), 371-383 (2008). (Pubitemid 351721718)
23. Dong Y, Feng SS: Poly(d,l-lactide-co-glycolide) (PLGA) nanoparticles prepared by high pressure homogenization for paclitaxel chemotherapy. Int. J. Pharm. 342(1-2), 208-214 (2007). (Pubitemid 47263496)
24. Pohlman B, Sweetenham J, Macklis RM: Review of clinical radioimmunotherapy. Expert Rev. Anticancer Ther. 6(3), 445-461 (2006). (Pubitemid 44192926)
25. Press OW, Shan D, Howell-Clark J et al.: Comparative metabolism and retention of Iodine-125, Yttrium-90, and Indium-111 radioimmunoconjugates by cancer cells. Cancer Res. 56(9), 2123-2129 (1996). (Pubitemid 26119913)